Seventeen peptide compounds that the FDA once placed on its list of bulk drug substances raising significant safety risks now sit in a table headed “nominated but withdrawn,” and the sales pages have read that as a clean bill of health. It is not one. The agency left its safety findings for those seventeen on the same public page, in the same words, and the person holding the syringe has not read a line of it.
Peptides side effects come in two kinds of answer, and only one of them carries a denominator. An approved product has its harms counted in trials and printed on a label a patient can read. A research-use-only vial has no count at all, and the FDA says so in writing on a page it dates 22 April 2026.
The one-sentence answer, before the detail: for peptides with an approved medicine behind them, side effects are measured, ranked and published, and for the seventeen compounds in the grey-market vials the trials that would produce those numbers have not been run, which is why the FDA’s own safety page states, compound by compound, that it lacks the information to know whether they cause harm.
Peptides Side Effects With a Label – PT-141 and the Numbers It Carries
PT-141 is bremelanotide, sold as Vyleesi and approved in the United States in 2019. Its label sits in DailyMed under a version published 18 November 2025, and the side-effect record inside it came from two identical 24-week randomized, double-blind, placebo-controlled trials in 1,247 premenopausal women, followed by a 52-week open-label extension that dosed another 684.
Those are the numbers that a peptide shop page leaves out:
- Nausea in 40% of patients, with anti-emetic treatment in 13%
- Discontinuation because of an adverse reaction in 18%, against 2% on placebo
- Serious adverse reactions in 1.1%, against 0.5% on placebo
- Reactions reported above 4%: nausea, flushing, injection site reactions, headache, vomiting
- Severity: mild in 31%, moderate in 40%
- Transient increases in blood pressure, reductions in heart rate, and focal hyperpigmentation
The label also carries one liver case from the open-label extension. A patient who had taken ten doses across a year arrived with liver enzymes above forty times the upper limit of normal and bilirubin six times the limit, and her liver tests returned to normal four months after she stopped the drug. The label states that a different cause was not identified and that the role of the medicine could not be ruled out.
Worth sitting with: a company with a marketing department wrote that down. One patient, ten doses, 1,247 women in the trials, and the frightening line published with a count attached.
Peptides Side Effects Without One – the Sentence the FDA Keeps Publishing
The same molecule sold as a research vial has no label, no denominator, and no company required to publish anything. The FDA’s safety page makes that visible in a table it calls “Bulk drug substances nominated but withdrawn.”
For BPC-157, the entry reads: “FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”
For KPV, MOTs-C, dihexa acetate, PEG-MGF and thymosin beta-4 fragment, the phrase is shorter and harder: “FDA has not identified any human exposure data on drug products containing” them via any route of administration.
Zero human exposure data is not the same as zero harm. It is the absence of the test that would tell a person which one they are looking at.
Melanotan II – Melanoma, Priapism and a File of Case Reports
Melanotan II moved people into the emergency room before the FDA wrote its summary, and the summary lists the damage by name. The agency’s entry notes a risk of immunogenicity from aggregation and peptide impurities, then states: “Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”
The rest of that withdrawn table reads like the back of a file that stays in the drawer at purchase:
- CJC-1295: “serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction”
- Cathelicidin LL-37: “Nonclinical research findings suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues”
- AOD-9604: “serious adverse events that may be associated with AOD-9604, though causality is not clear”
- Ipamorelin acetate: “a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility”
A case report is a signal, not a rate, and this page will not pretend otherwise. It still says more than a product page, which reports nothing at all.
What Left the List – the Nominators Walked Out, the Data Did Not Arrive
A category placement is procedural status, and the FDA’s own documents show how it moves. Its safety page describes the withdrawn list as substances “previously in category 2 of the interim policies” that “were withdrawn by the nominators.”
The GHK-Cu entry in the agency’s 503A categories document, updated 14 May 2026, shows the machinery in one compound. GHK-Cu for non-injectable routes came out of category 1 on 22 April 2026 “because the nominations for GHK-Cu were withdrawn by the nominators.” On 5 May 2026 a nominator clarified that it intended to withdraw only the injectable route, so the non-injectable nomination went back into category 1. The FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu belongs on the 503A bulks list at all.
Nominations move. Labels do not appear.
Still Flagged – Three Peptides the FDA Names Without Hedging
Category 2, the tier for substances that raise significant safety risks, holds six entries under the 503A interim policy in the agency’s document dated 14 May 2026: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine hydrochloride for intrauterine use.
Three of those sit in the peptide market’s own aisle:
- Ibutamoren mesylate, sold as MK-677, in category 2 for 503A since 29 September 2023: “poses significant safety risks due to the potential for congestive heart failure in certain patients”
- GHRP-6, in category 2 for 503B since 29 September 2023: a risk of immunogenicity, plus “potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity”
- Kisspeptin-10, in category 2 for 503A since 29 September 2023: immunogenicity risk, complexity in characterizing the ingredient, and the agency’s note that it has “no, or only limited, safety-related information” for the routes being sold
Ipamorelin acetate makes the contradiction plainest of all. It sits in the withdrawn table under the 503A policy and in the category 2 table under the 503B policy, on the FDA’s own pages, at the same time.
The peptide class did not get cleared in 2026. Part of it still sits on the do-not-compound side of the agency’s sheet.
The July Meeting – a Recommendation Is Not a Permission
The FDA’s advisory-committee page states the rule in one line: “Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.”
The July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee had seven substances on its agenda, listed on FDA’s own page with the uses the agency reviewed: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTs-C for obesity and osteoporosis on the first day, then emideltide, also called DSIP, for opioid withdrawal and sleep disorders, Semax for cerebral ischemia and migraine, and Epitalon for insomnia on the second. The Federal Register notice ran 16 April 2026 at 91 FR 20465 under docket FDA-2025-N-6895, and the comment docket closed 22 July 2026.
Not one of those seven is an FDA-approved drug, at the meeting or after it. The 503A bulks list, the list that decides what a licensed pharmacy may compound with, holds six substances from the February 2019 final rule, and the FDA’s compounding page says exactly that. None of the six is a peptide.
A committee answered a question about a list. The list has not moved.
What to Ask Instead of What You Are Being Told
A clinic selling peptides can answer three things in writing, and the answers are checkable: which approved product contains this molecule, which trial measured its side effects, and where is that label. An answer of research use only is not an answer, and this directory will say uncertainty out loud.
For the compounding background behind those answers, read are peptides steroids and peptides explained: the FDA list. If a seller hands you a reconstitution chart as proof, start with why a peptide calculator is not a dose.
Frequently asked questions – Peptides Side Effects People Search For
What are the most common side effects of peptides?
It depends entirely on whether an approved product exists for the molecule. Bremelanotide’s label reports nausea in 40% of patients, flushing, injection site reactions, headache and vomiting above 4%, and discontinuation in 18% of trial participants. For the compounds sold as research chemicals, there is no measured rate to quote, because no one has run the trials that produce one. The FDA lists immunogenicity from peptide-related impurities as a concern across that second group.
What are BPC-157’s side effects?
The FDA’s own safety entry says it has “identified no, or only limited, safety-related information for the proposed routes of administration” and “lacks sufficient information to know whether the drug would cause harm when administered to humans.” Its listed concerns are immune reactions tied to certain routes and the difficulty of characterizing the ingredient. Anyone quoting a side-effect percentage for BPC-157 is quoting a guess.
Are peptide injections safe long term?
For unapproved peptides, that question has no answer, because the data do not exist. Bremelanotide’s record covers 24 weeks of controlled dosing plus a 52-week extension, and that is a long trial by wellness standards. A one-year window still leaves a decade of unknowns, which is why this page calls it unresolved rather than safe.
What are the side effects of PT-141?
Nausea in 40%, anti-emetic treatment in 13%, flushing, injection-site reactions, headache and vomiting, transient blood pressure increases with heart-rate reductions, and focal hyperpigmentation. The discontinuation rate for adverse reactions ran 18% against 2% on placebo, and serious adverse reactions ran 1.1% against 0.5%. One liver case appears in the extension data, with enzymes above forty times the normal limit and recovery four months after the drug stopped.
Do peptides side effects differ for men and women?
The trials that produced usable numbers enrolled narrow groups, so the honest answer for anyone outside those groups is that the measurement was not done. Bremelanotide’s two pivotal trials studied premenopausal women aged 19 to 56. A confident claim about men on PT-141 has no trial behind it. For the unapproved compounds, there is not enough human data to compare the groups at all.
Why did those peptides come off the FDA’s safety-risks list?
Because the nominations were withdrawn, which is what the FDA’s page says in its heading and its text. That is a change in procedural status, not a finding of safety. Removing a substance from category 2 does not put it on the 503A bulks list, and the safety summary FDA wrote for it stays published on the same page.
Are compounded peptides FDA-approved?
No. Approval belongs to a specific product and a specific application. A compounded peptide has neither, and the FDA has described research-use-only marketing as evidence that a product is an unapproved new drug. A compounded product made by a licensed pharmacy under a prescription sits in a different lane from an approved medicine, and that lane is not approval.
Sources: FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA, Bulk Drug Substances Used in Compounding Under Section 503A, FDA, 503A categories document updated 14 May 2026, Federal Register, Pharmacy Compounding Advisory Committee meeting notice, 16 April 2026, DailyMed, Vyleesi (bremelanotide) label, published 18 November 2025, FDA, Pharmacy Compounding Advisory Committee, July 23-24 2026.
Whether a clinic may legally hand any of that to you is a separate question, and three state medical boards answered it in writing during 2026: are peptides legal, and where the answer changed.